Navigation Links
Researchers to develop next generation immunotherapy for children with deadly solid tumors
Date:4/3/2013

Recently, research using adoptive T-cell immunotherapy in blood cancers have shown success, most notably in the case of a seven-year-old girl whose leukemia went into remission using altered T-cells and a disabled HIV virus. Now, two of the pediatric cancer scientists involved in the T-cell/HIV study will develop a new experimental cancer immunotherapy treatment option for children with high-risk solid tumors based on the same novel approach that uses a patient's own T-cells to attack tumor cells.

Researchers at the Children's Hospital of Philadelphia, the University of Pennsylvania, and the Primary Children's Medical Center of Salt Lake City received a $550,000 collaborative grant to test next generation T-cell immunotherapy strategies in children with neuroblastoma, a solid tumor with poor prognosis that is responsible for 15% of all childhood cancer deaths. The awardees were selected within a rigorous peer-review process through a new initiative called ACT FAST (Adoptive Cell Therapy For Adolescent/pediatric Solid Tumor), which is spearheaded by Solving Kids' Cancer. ACT FAST aims to fast-track promising research into a clinical trial within one year of the award through a collaborative team of researchers.

"Only a handful of cancer centers in the world have the capabilities and the infrastructure to implement adoptive cell therapy," said Scott Kennedy, the Executive Director of Solving Kids' Cancer. "Our goal in bringing together these researchers and institutions was to harness their collective power in bringing faster cures to kids with neuroblastoma."

The National Cancer Institute (NCI) and the Society for the Immunotherapy of Cancer (SITC) provided strategic counsel and expert review of the grant award, which was jointly funded by Solving Kids' Cancer, the Pierce Phillips Charity, and the Catherine Elizabeth Blair Memorial Foundation.

The clinical trial will be the first to use transiently modified T-cells in children with neuroblastoma and is estimated to open before the end of the year. Stephan Grupp, M.D., Ph.D., Professor of Pediatrics at the Children's Hospital of Philadelphia, will direct the trial in collaboration with Michael Pulsipher, M.D., Professor of Pediatrics at the Primary Children's Medical Center/University of Utah, and Carl June, M.D., the Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, who led the altered T-cell/HIV study.

Today, children with relapsed high-risk neuroblastoma have little or no options to cure their disease through traditional methods, including chemotherapy, surgery and radiation. Early clinical studies utilizing cancer immunotherapies such as modified T-cells have demonstrated initial success and promising potential as more effective treatment options in some blood cancers, including chronic myelogenous leukemia in adults and acute lymphoblastic leukemia in children.

"The ACT FAST initiative aims to bring the newest engineered T cell therapies to pediatric solid tumors. The ACT FAST approach is rigorous, highly focused and intensely translational. By collaborating with pediatric physician-scientists across institutions through ACT FAST, we will not only be able to advance research into engineered T-cell treatments, but just as importantly, offer cutting-edge cancer immunotherapy clinical trial options rapidly to children whose cancer recurs or resists current treatment," said Dr. Grupp.


'/>"/>

Contact: Jenny Song
jenny@solvingkidscancer.org
212-588-6625
Solving Kids' Cancer
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: